Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Patent - MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY
https://patents.justia.com/patent/20220151986
Patents Assigned to Mind Medicine, Inc.
https://patents.justia.com/assignee/mind-medicine-inc
Here we go again. Pay attention. Read my post dated 08/28
I WILL buy back in. But not now
GLTA
Shit show. Let’s all reach out to MindMed by whatever means and give them hell. Bags of potential this company & stock but they seem to have no idea how to maintain or develop investor sentiment / interest. That CEO Barrow might possess some strengths but being a well-rounded, communicative CEO is not one of them. What a weak twat this far.
VERY good thing you're paying attention and noticed the RS....
Speaking of paying attention. The rest of the market hasn’t gone through a reverse split.
I WILL buy back in. But not now
GLTA
That EXACT statement can apply to the ENTIRE market. Unless you're not paying attention....
I will be a buyer at $4.25 in 2 weeks...sad so sad...
Yes, MindMed's leadership is weak in this regard. Very frustrating and I bet they have lost a ton more investors of late as a direct consequence. "All the gear but no f#cking idea" is the famous quote that springs to mind..
The_Slow_Bleed_Continues_After_Reverse_Split
Wish MNMD would do something PR wise to prop up support.
MindMed Collaborators Dose First Subject in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances:
First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in healthy subjects. Acute effects of equivalent doses will be compared across the following compounds: MDMA, MDA, Lys-MDMA and Lys-MDA.
NEW YORK, Sept. 20, 2022 -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first subject has been dosed in a Phase 1 investigator-initiated study led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB). The study aims to evaluate the effects of MDMA-like substances, including MDA, Lys-MDMA, Lys-MDA, versus a placebo in healthy volunteers.
"Although amphetamines like MDMA and MDA induce mainly positive subjective and mood-enhancing effects, they may also produce negative subjective drug effects, particularly at the onset of response," said Prof. Matthias Liechti, principal investigator of the trial. "Lys-MDMA and Lys-MDA are prodrugs that are slowly metabolized to MDMA and MDA, offering a novel and controlled delivery system of these active substances with potentially improved pharmacological properties. By using pharmacokinetics and modern psychological and psychometric tests, this study will investigate the potential to better control the bioavailability, slow the effect onset and reduce possible adverse effects of MDMA and MDA by using these prodrugs. The study will also investigate effects of MDA in direct comparison with MDMA for the first time in humans."
Dr. Miri Halperin Wernli, Executive President of MindMed, added, "This study represents an exciting opportunity to investigate the pharmacokinetic and pharmacodynamic activity of MDMA-like compounds within the same subject. Through our collaboration with the Leichti Lab at UHB, we have exclusive rights to the data from this study which will enhance our understanding of the therapeutic properties involved in the induction of positive mood in a way that may help optimize the treatment model for our R(-)-MDMA drug candidate."
The Phase 1 clinical trial is a randomized, placebo-controlled, double-blinded, 5-period crossover study. The trial plans to enroll 24 healthy subjects who will receive MDMA (100mg), MDA (93.9mg), Lys-MDMA (171.7 mg), Lys-MDA (165.6 mg), and placebo. The primary outcome measures for this study will assess acute subjective effects using Visual Analog Scales (VAS) assessing the intensity and duration of subjective effects on a scale (0-100 percent) with higher scores representing more intense effects as well as plasma levels of MDMA and MDA at each study day across the 18-month study period. More information about the trial is available on our website (mindmed.co) or on clinicaltrials.gov (identifier NCT04847206).
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Until SEC gives a damn about this type venue, there will never be an honest playing field in US equities markets... Sooooo many corps have done these R/S self-wealth enrichment schemes over the years. Just personal ATM's for the Insiders...
We could see 5 and end up in the mid 4's by the end of the week....shorters are in control...lol
5.00 by end of week here??? Sickening to see, SEC don't care, always happens cause more of today's CEO's and BOD are greed driven- not caring of their companies like in old days...
Yup we will see under 7 today from this scam.....my guess is 6.79 =.45 lol.....sad so sad...
https://www.fool.com/investing/2022/09/15/why-cruise-line-stocks-popped-again-on-thursday/
(shared via bit.ly/mystocksapp)
Crooked companies with crooked management do this all the time. NO different than current Federal Govt Administration who know NOTHING about running a business and run it into ground, hurting the very People who thought to support it Legitimately ... ~
Sorry for your loss. I'll let you know one way or the other when I see fit.
You can have my 333 shares as an Original Investor in this scam...
I'm no spring chicken but thanks for your concern. I have a small starter position here and will decide on my own whether to add to it or not.
Let me tell you what this is as an old timer... Another Fkng WASH, RINSE, REPEAT PERSONAL ATM OPERATION FOR ALL THE INSIDERS....
Just BS stories being printed on every brokerage account like the R/S was good and decent, when in truth, had they done stock buyback you would see huge double digit gains- not double digit losses as this drifts down toward 1.00 level daily sadly..
Then what can they do then?? ONLY a new "Offering" to dillute shares which increases public amount of shares out there; everyone loses except Insiders in these insane ATM's which SEC too damn dumb to stop...
Was that 7.20 l just saw printed....OMG!!!!
Lol....here is my .50 prediction l made a month ago prior the reverse...now let's hit .40 = 6.00 in today's pricing...what a bunch of clowns....sad so sad...
Fell below massive 8.00 support level. Where it goes form here is anyones' guess...
Corporate Deck - August 2022
https://mindmed.co/wp-content/uploads/2022/08/MindMed_CorpDeck_Aug22_2022_Final.pdf
I hear you there... But problem as a whole in US; < is nobody really gives a FUCK ABOUT HELPING ANYONE WITH MENTAL ILLNESS !!
I HAVE 1ST HAND PERSONAL KNOWLEDGE TO THIS DEALING WITH EVERYONE FROM MEDICAL COMMUNITY TO LAW ENFORCEMENT, COURTS, ETC.. IT/THEY ARE ALL ONE BIG MONEY MAKING SCHEME AND VERY FEW PEOPLE ARE HELPED OUT THERE SADLY...
MindMed
After some much-needed positive news for investors, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), reversed course and recovered with a great trading day on Thursday. This came after the company released some positive results from a clinical trial involving anxiety patients who received LSD as a placebo, in doses that were regulated.
In contrast to conventional LSD, which can relieve anxiety symptoms for up to four weeks with just one dose, MindMed’s patented MM-120 product seemed to provide patients with better advantages and benefits.
Commenting on this positive results, Rob Barrow, CEO and Director of MindMed, stated: “This paper further reinforces the positive preliminary evidence for LSD in patients who suffer from anxiety disorders. Acute administration of LSD produced long-lasting and notable reductions of anxiety and comorbid depression symptoms for up to 16 weeks. These results are encouraging and supportive of our proprietary MM-120 product candidate in its potential to one day offer a therapeutic benefit for patients suffering from GAD after just a single-dose administration.”
https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-110039568.html
(shared via bit.ly/mystocksapp)
lol.. I know. I meant buy more or stay in.
What? I never got out. I was considering halving my position last week though.
You know what's going on... get back in.
The weak & desperate have likely transferred their shares over to the strong and confident by now. Lining up my next buy (add) in fact. We’ll see.
Market cap wise I am not concerned with this going to 1.00 that is a bit extreme.
I'm holding and buying. As I always have.
Strong support at 8.00 level, but if that breaks it has nothing down to 1.00 sadly... Will see what comes of this mess...
?? It just went down another Dollar Friday...
They should have done a share buy back like serious companies do so they enhance Shareholders- Not destroy them with valuation decay like this...
This is going to get juicy....
Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD
https://www.cell.com/neuron/fulltext/S0896-6273(22)00752-8#relatedArticles
Bryan Roth is on MindMed's team:
https://www.prnewswire.com/news-releases/mindmed-appoints-university-of-north-carolina-psychiatrist-and-pharmacologist-dr-bryan-roth-to-scientific-advisory-board-301387396.html
New Patent: ($MNMD) USING GENO-
OR PHENOTYPING TO ADJUST LSD
DOSING
https://appft.uspto.gov/netacgi/nph-Parser?
Sect1=PT02&Sect2=HITOFF&p=1&u=%2Fnetaht
mI%2FPTO%2Fsearch-
adv.htm|&r=1&f=G&1=50&d=PG01851=20220280
501&0S=20220280501&RS=20220280501
Patent Alert! A new U.S. patent application No.
20220280501 was published yesterday
containing broad claims regarding the use of
#genetic and #metabolic assessment to
determine #sd #dosing. Prior art can be found at
http://portasophia.org
LSD-assisted therapy induces rapid and lasting reductions in anxiety and depression symptoms, according to new research
https://www.psypost.org/2022/09/lsd-assisted-therapy-induces-rapid-and-lasting-reductions-in-anxiety-and-depression-symptoms-according-to-new-research-63870
Headlines rolling in...
LSD trial shows promising results for Generalised Anxiety Disorder
https://psychedelichealth-co-uk.cdn.ampproject.org/c/s/psychedelichealth.co.uk/2022/09/08/lsd-trial-shows-promising-results-for-generalised-anxiety-disorder/amp/
What’s your story with todays move and news?
MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
https://www.newswire.ca/news-releases/mindmed-announces-positive-results-from-collaborators-placebo-controlled-investigator-initiated-trial-published-in-peer-reviewed-journal-811111788.html
NEWS PROVIDED BY
Mind Medicine (MindMed) Inc.
Sep 08, 2022, 07:30 ET
- Data from University Hospital Basel (UHB) study supports the clinical development of MindMed's proprietary MM-120 product candidate for Generalized Anxiety Disorder ("GAD") –
- Patient dosing in Phase 2b trial ongoing for MM-120 in GAD–
- MindMed currently owns and retains all clinical data and manufacturing rights for MM-120 and intends to continue broadening its intellectual property portfolio -
NEW YORK, Sept. 8, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that the manuscript "Lysergic Acid Diethylamide-Assisted Therapy In Patients With Anxiety With And Without A Life-Threatening Illness A Randomized, Double-Blind, Placebo-Controlled Phase II Study," has been published in the peer-reviewed scientific journal Biological Psychiatry. The paper expands on previously reported positive data that was featured in an oral presentation at the PSYCH Symposium in London on May 11, 2022.
Rob Barrow, CEO and Director of MindMed, stated: "This paper further reinforces the positive preliminary evidence for LSD in patients who suffer from anxiety disorders. Acute administration of LSD produced long-lasting and notable reductions of anxiety and comorbid depression symptoms for up to 16 weeks. These results are encouraging and supportive of our proprietary MM-120 product candidate in its potential to one day offer a therapeutic benefit for patients suffering from GAD after just a single-dose administration."
"Patient dosing in our Phase 2b trial for MM-120 is ongoing and we are continuing to leverage this momentum in our mission to bring our novel therapeutic option to market. We believe MM-120 has a highly attractive commercial opportunity given its potential benefits for GAD patients. We also continue to advance our efforts to further strengthen the protection of our intellectual property and proprietary technology that is important to our business. Our exclusive rights to the data from this study through our strong and productive collaboration with the Liechti Lab at UHB only enhance our leading position in the development of MM-120. We continue to protect and build on this position by filing multiple layers of intellectual property applications and continue to retain clinical data, manufacturing rights to and know-how for our proprietary MM-120 product, which we believe offers significant advantages as a pharmaceutical product over the free-base form of LSD."
Daniel R. Karlin, MD, MA, Chief Medical Officer of MindMed, added, "GAD is a debilitating mental health disorder that is often insufficiently managed with available medications and can significantly impair one's ability to function. We are encouraged by the lasting effects observed in this robust clinical study, which further highlights the therapeutic potential of MM-120 to address the unmet need for novel treatment options."
About MM-120 (LSD D-Tartrate) and Phase 2b Trial in GAD
MindMed's lead drug candidate, MM-120, is a proprietary, pharmaceutically optimized form of LSD D-Tartrate that is separate from the free-base form of LSD (CAS-50-37-3).
The Company also has a broad, multi-year exclusive research partnership with UHB in addition to exclusive worldwide rights to data, compounds and patent rights associated with UHB's research on LSD and other compounds, including data from preclinical studies and ongoing LSD trials.
The Phase 2b trial in patients diagnosed with GAD is a multi-center, parallel, randomized, double-blind, placebo-controlled, dose-optimization study. The trial is expected to enroll 200 participants who will receive a single administration of up to 200 µg of MM-120 or placebo.
The primary objective is to determine the reduction in anxiety symptoms four weeks after a single administration of MM-120, compared across the five treatment arms. Key secondary objectives, measured up to 12 weeks after the single administration, include assessments of safety and tolerability as well as quality of life. More information about the trial is available on MindMed's website (mindmed.co) or on clinicaltrials.gov (NCT05407064).
About MindMed's Intellectual Property Strategy
As detailed in the Company's 2022 annual report on Form 10-K, MindMed's patent strategy includes pursuing protection for compositions of matter, methods of treatment, and diagnostic devices and analytics related to psychedelics. MindMed's patent portfolio includes 26 pending U.S. applications, and 12 pending Patent Cooperation Treaty (PCT) applications. If granted, patents based on these applications have a projected expiry date beginning in 2040.
The Company intends to continue its multifaceted strategy of seeking and maintaining patents intended to cover its product candidates and compositions, their methods of use and processes for their manufacture, and any other aspects of inventions or applications such as digital medicine approaches that are commercially important to the development of our business. We retain all rights to the intellectual property we have acquired and developed internally and remain highly confident in our intellectual property strategy.
Not to say I told you so but….
Now, the mushrooming question is when to buy back in?
GLTA
Followers
|
195
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
9394
|
Created
|
02/18/20
|
Type
|
Free
|
Moderators MomsSpaghetti Savannah-Marc |
Location: New York, NY / Toronto, Ontario
Flagship Products: LSD, 18-MC and other psychedelics
Treatment Focus: Addiction, ADHD, Anxiety, Depression, Headaches
Ticker: $MNMD (NASDAQ), $MMED (NEO), $MMQ (DAX),
Financial Reports: Link
SEC Filings: Link
SEDAR Filings: Link
IN THE MEDIA
”Could the Embrace of Psychedelics Lead to a Mental-Health Revolution?”, Vogue
”Psychedelics-Drug Startup Raises $24 Million Ahead of IPO”, Wall Street Journal
”Silicon Valley’s psychedelic wonder drug is almost here”, Fast Company
”Psychedelic drug company MindMed applies for nasdaq up-listing”, Forbes
”Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution”, Fortune
”A startup that wants to use psychedelics to treat addiction just raised $6.2 million from the host of Shark Tank and the architect behind the world’s biggest cannabis grower”, Business Insider
”New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center”, The New Yorker
”MindMed surges, putting it at the forefront of psychedelic euphoria”, Bloomberg
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |